A Potential First Treatment for Stargardt Disease

Data from the phase 3 DRAGON trial support tinlarebant as a treatment for the inherited retinal disorder. Belite Bio has completed a rolling NDA submission to the FDA.

By: Quan Dong Nguyen, MD, Diana V. Do, MD

Retinal Physician June 23, 2026

Clinical Report: A Potential First Treatment for Stargardt Disease

Overview

The phase 3 DRAGON trial demonstrated that tinlarebant slows lesion progression in Stargardt disease compared to placebo. Belite Bio has submitted a New Drug Application to the FDA for this oral treatment.

Background

Stargardt disease is the most common inherited macular dystrophy, affecting approximately 1 in 10,000 individuals. Current management options are limited to supportive care.

Data Highlights

Outcome Measure	Result
DDAF Lesion Growth Reduction	35.7% vs. placebo (p=0.0033)
Visual Acuity Changes	Minimal over 24 months
Patient Tolerance	Well tolerated with minimal adverse effects

Key Findings

Tinlarebant (5 mg daily) significantly slowed lesion progression in Stargardt disease.
The phase 3 DRAGON trial included 104 adolescents with a 2:1 randomization.
Primary endpoint met with a 35.7% reduction in DDAF lesion growth compared to placebo.
Visual acuity changes were minimal in both treatment and placebo groups over 24 months.
No systemic side effects were reported, and adverse visual phenomena were minimal.

Clinical Implications

Clinicians should monitor the FDA's decision on the drug's approval.

Conclusion

The results from the phase 3 DRAGON trial indicate the efficacy of tinlarebant in the treatment of Stargardt disease, pending FDA approval.

PentaVision

Retinal Physician